Drug
Sparc1203
Sparc1203: highest development phase Phase 2, developed by Sun Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Sun Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| SPARC1203 NCT01614691 | Phase 2 | Allergic Rhinitis |
Latest
No recent events.
Follow Sparc1203 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.